98
Participants
Start Date
September 12, 2021
Primary Completion Date
October 28, 2024
Study Completion Date
June 2, 2026
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
Research Site, Berlin
Research Site, Córdoba
Research Site, Silver Spring
Research Site, León
Research Site, Madrid
Research Site, Málaga
Research Site, Murcia
Research Site, Hanover
Research Site, Oviedo
Research Site, Padua
Research Site, Verona
Research Site, Seville
Research Site, Valencia
Research Site, Meldola
Research Site, Florence
Research Site, Cologne
Research Site, Cologne
Research Site, Tel Litwinsky
Research Site, Napoli
Research Site, Beersheba
Research Site, Messina
Research Site, Beijing
Research Site, Beijing
Research Site, Shenyang
Research Site, Jinan
Research Site, Tianjin
Research Site, Ganzhou
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Kfar Saba
Research Site, Tel Aviv
Research Site, Jerusalem
Research Site, Jerusalem
Research Site, Boston
Research Site, München
Research Site, Roma
Research Site, Terni
Research Site, Alicante
Research Site, Barcelona
Research Site, Palma de Mallorca
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY